[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2002364612A8 - Methods and materials for modulating enac-beta - Google Patents

Methods and materials for modulating enac-beta

Info

Publication number
AU2002364612A8
AU2002364612A8 AU2002364612A AU2002364612A AU2002364612A8 AU 2002364612 A8 AU2002364612 A8 AU 2002364612A8 AU 2002364612 A AU2002364612 A AU 2002364612A AU 2002364612 A AU2002364612 A AU 2002364612A AU 2002364612 A8 AU2002364612 A8 AU 2002364612A8
Authority
AU
Australia
Prior art keywords
beta
materials
methods
enac
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002364612A
Other versions
AU2002364612A1 (en
Inventor
Samuel J Shuster
Laura S Stone
Hong-Yan Zhang
Ulf N G Arvidsson
Lucy Vulchanova Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALGOS THERAPEUTICS Inc
Original Assignee
ALGOS THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALGOS THERAPEUTICS Inc filed Critical ALGOS THERAPEUTICS Inc
Publication of AU2002364612A8 publication Critical patent/AU2002364612A8/en
Publication of AU2002364612A1 publication Critical patent/AU2002364612A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002364612A 2001-12-31 2002-12-31 METHODS AND MATERIALS FOR MODULATING ENaC-BETA Abandoned AU2002364612A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34606901P 2001-12-31 2001-12-31
US60/346,069 2001-12-31
PCT/US2002/041850 WO2003057847A2 (en) 2001-12-31 2002-12-31 METHODS AND MATERIALS FOR MODULATING ENaC-BETA

Publications (2)

Publication Number Publication Date
AU2002364612A8 true AU2002364612A8 (en) 2003-07-24
AU2002364612A1 AU2002364612A1 (en) 2003-07-24

Family

ID=23357796

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002364612A Abandoned AU2002364612A1 (en) 2001-12-31 2002-12-31 METHODS AND MATERIALS FOR MODULATING ENaC-BETA

Country Status (3)

Country Link
EP (1) EP1478655A4 (en)
AU (1) AU2002364612A1 (en)
WO (1) WO2003057847A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2376400A1 (en) 1999-06-08 2000-12-14 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
AR066984A1 (en) 2007-06-15 2009-09-23 Novartis Ag INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
WO2011131707A1 (en) 2010-04-23 2011-10-27 Novartis Ag ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
WO2013155406A1 (en) * 2012-04-12 2013-10-17 The Chinese University Of Hong Kong Contragestion and treating inflammation by modulating sodium channel activity in the epithelium
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
CA3016985C (en) 2016-03-07 2023-07-04 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
BR112019023650A2 (en) 2017-07-06 2020-06-02 Arrowhead Pharmaceuticals, Inc. RNAI AGENTS TO INHIBIT ALFA-ENAC EXPRESSION AND METHODS OF USE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975798A1 (en) * 1997-03-11 2000-02-02 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
US20030077773A1 (en) * 2000-12-06 2003-04-24 Brandon Rhonda C. Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof

Also Published As

Publication number Publication date
WO2003057847A2 (en) 2003-07-17
EP1478655A4 (en) 2006-05-10
WO2003057847A3 (en) 2003-12-11
AU2002364612A1 (en) 2003-07-24
EP1478655A2 (en) 2004-11-24
WO2003057847A8 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
EP1423120A4 (en) 2h-phthalazin-1-ones and methods for use thereof
AU2002352903A8 (en) Mesoporous materials and methods
GB0128287D0 (en) Novel method and compounds
GB0115980D0 (en) Apparatus and methods
IL158750A0 (en) Reagents and methods for modulating dkk-mediated interactions
EP1434772A4 (en) Compounds and methods
GB0123379D0 (en) Modulators
AU2002364610A8 (en) Methods and materials for modulating trpc4
GB0102646D0 (en) Recording material and method
AU2002359694A8 (en) Compounds and methods
AU2002364612A8 (en) Methods and materials for modulating enac-beta
GB0114533D0 (en) Substances
GB0107628D0 (en) Substances
EP1379240A4 (en) Compounds and methods
GB0115071D0 (en) Substances
AU2002367320A8 (en) Methods and materials for modulating task-3
AU2002360847A8 (en) Methods and materials for modulating p2x2
AU2003298921A8 (en) Methods and materials for modulating trpm2
GB0116185D0 (en) Substances
GB0127602D0 (en) Materials and methods for modulating t-cell activity
GB0115782D0 (en) Assays and modulators
AU2002247441A1 (en) Compounds and methods
AU2002245725A1 (en) Compounds and methods
AU2002254470A1 (en) Compounds and methods
AU2002335011A1 (en) Compounds and methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase